Overview

Global Epilepsy Therapeutics Market is estimated to value over USD 15.2 billion by 2026 end and register a CAGR of over 3.2% during the forecast period 2019 to 2026.

The epilepsy therapeutics market growth can be attributed to the increasing incidences of neuron-related disorders and advancements in technology in treating these conditions. Furthermore, factors, for instance, growing awareness regarding treatment and diagnostics of neurological disorders are steering the market growth. Epilepsy is a neurological disorder in which the patient undergoes recurring involuntary seizures. These seizures may be categorised as generalized seizures, focal seizures and others. Focal seizures are commonly observed seizures in epilepsy patients which includes complex partial seizures and secondary generalised clonic or tonic seizures. 

Growing awareness and advancements in technology in the field of neurology is further stimulating the market growth. Furthermore, initiatives taken by the government in this field are also steering this market. Nonetheless, factors like a dearth of awareness regarding the condition in some emerging regions and reduction in adoption of epilepsy medications due to reluctance from patients are impeding the market growth globally. 

The second generation epilepsy therapeutics is predicted to account for a significant epilepsy therapeutics market share due to their better efficiency in comparison to first generation epilepsy therapeutics and increased market penetration. The third-generation epilepsy therapeutics have fewer side effects as compared to the first and second generation epilepsy therapeutics and are considered having a high efficacy; thus, this segment is predicted to grow with a substantial CAGR over the forecast timeframe. 

 

Key market players included in the global epilepsy therapeutics industry are Pfizer Inc., UCB S.A, Bausch Health Companies Inc., Novartis AG, GlaxoSmithKline PLC, Teva Pharmaceutical Industries, Sunovion Pharmaceuticals Inc., Eisai Co. Ltd., Upsher-Smith Laboratories LLC, Amneal Pharmaceuticals LLC.

 

Epilepsy Therapeutics Market Segmentation:

By Product

  • First Generation Epilepsy Therapeutics
  • Second Generation Epilepsy Therapeutics
  • Third Generation Epilepsy Therapeutics

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

 

Objectives of the Study:

  • To provide with an exhaustive analysis on the epilepsy therapeutics market by product, by distribution channel and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
  • To forecast and evaluate micro-markets and the overall market 
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
  • To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers

$3450

Need Assistance

--------

UK : +44 141 628 9353
US : +1 347 709 4931

OR

Contact Sales

What you get


  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included


  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics